JPS6351337A - 抗腫瘍剤 - Google Patents
抗腫瘍剤Info
- Publication number
- JPS6351337A JPS6351337A JP61196629A JP19662986A JPS6351337A JP S6351337 A JPS6351337 A JP S6351337A JP 61196629 A JP61196629 A JP 61196629A JP 19662986 A JP19662986 A JP 19662986A JP S6351337 A JPS6351337 A JP S6351337A
- Authority
- JP
- Japan
- Prior art keywords
- lactoferrin
- iron
- antitumor agent
- ferric
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 19
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 64
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 41
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 41
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 37
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 37
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 37
- 229910052742 iron Inorganic materials 0.000 claims abstract description 30
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229910001447 ferric ion Inorganic materials 0.000 claims abstract description 11
- 235000013336 milk Nutrition 0.000 claims abstract description 8
- 239000008267 milk Substances 0.000 claims abstract description 8
- 210000004080 milk Anatomy 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003978 infusion fluid Substances 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 239000013522 chelant Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 229910021578 Iron(III) chloride Inorganic materials 0.000 abstract description 4
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 abstract description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 abstract description 3
- 229910000360 iron(III) sulfate Inorganic materials 0.000 abstract description 3
- 230000002378 acidificating effect Effects 0.000 abstract description 2
- 150000002500 ions Chemical class 0.000 abstract description 2
- 238000001042 affinity chromatography Methods 0.000 abstract 1
- 230000000356 anti-lactoferrin effect Effects 0.000 abstract 1
- 238000004925 denaturation Methods 0.000 abstract 1
- 230000036425 denaturation Effects 0.000 abstract 1
- 230000003100 immobilizing effect Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003278 haem Chemical group 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61196629A JPS6351337A (ja) | 1986-08-22 | 1986-08-22 | 抗腫瘍剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61196629A JPS6351337A (ja) | 1986-08-22 | 1986-08-22 | 抗腫瘍剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6351337A true JPS6351337A (ja) | 1988-03-04 |
| JPH0586932B2 JPH0586932B2 (de) | 1993-12-14 |
Family
ID=16360940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61196629A Granted JPS6351337A (ja) | 1986-08-22 | 1986-08-22 | 抗腫瘍剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6351337A (de) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116953A (en) * | 1988-10-17 | 1992-05-26 | Snow Brand Milk Products Co., Ltd. | Method for thermally treating lactoferrin |
| WO1994019375A1 (en) * | 1993-02-16 | 1994-09-01 | Snow Brand Milk Products Co., Ltd. | Iron-lactoferrin combination and process for producing the same |
| WO2002043752A1 (fr) * | 2000-11-29 | 2002-06-06 | Morinaga Milk Industry Co., Ltd. | Agents therapeutiques de potentialisation d'effet a base d'interferon |
| WO2005089788A1 (ja) | 2004-03-19 | 2005-09-29 | Morinaga Milk Industry Co., Ltd. | 癌治療のための薬剤 |
| JP2005533029A (ja) * | 2002-05-10 | 2005-11-04 | エイジェニックス・インコーポレイテッド | 悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン本願は、米国仮特許出願第６０／３７９，４４２号（２００２年５月１０日出願）、米国仮特許出願第６０／３７９，４４１号（２００２年５月１０日出願）および米国仮特許出願第６０／３７９，４７４号（２００２年５月１０日出願）に基づく優先権を主張するものであり、それらの内容は、この引用により本明細書に記載されたものとする。 |
| US8105615B2 (en) | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4592041B2 (ja) * | 2000-11-24 | 2010-12-01 | 株式会社Ｎｒｌファーマ | 生活の質を改善する新規食品の製造法および用途 |
-
1986
- 1986-08-22 JP JP61196629A patent/JPS6351337A/ja active Granted
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116953A (en) * | 1988-10-17 | 1992-05-26 | Snow Brand Milk Products Co., Ltd. | Method for thermally treating lactoferrin |
| WO1994019375A1 (en) * | 1993-02-16 | 1994-09-01 | Snow Brand Milk Products Co., Ltd. | Iron-lactoferrin combination and process for producing the same |
| WO2002043752A1 (fr) * | 2000-11-29 | 2002-06-06 | Morinaga Milk Industry Co., Ltd. | Agents therapeutiques de potentialisation d'effet a base d'interferon |
| JP2005533029A (ja) * | 2002-05-10 | 2005-11-04 | エイジェニックス・インコーポレイテッド | 悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン本願は、米国仮特許出願第６０／３７９，４４２号（２００２年５月１０日出願）、米国仮特許出願第６０／３７９，４４１号（２００２年５月１０日出願）および米国仮特許出願第６０／３７９，４７４号（２００２年５月１０日出願）に基づく優先権を主張するものであり、それらの内容は、この引用により本明細書に記載されたものとする。 |
| US7901879B2 (en) | 2002-05-10 | 2011-03-08 | Agennix Incorporated | Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| JP2011079858A (ja) * | 2002-05-10 | 2011-04-21 | Agennix Inc | 定着固形癌の治療におけるラクトフェリン |
| JP4685443B2 (ja) * | 2002-05-10 | 2011-05-18 | エイジェニックス・インコーポレイテッド | 悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン |
| US8242079B2 (en) | 2002-05-10 | 2012-08-14 | Agennix Incorporated | Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| US8105615B2 (en) | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| WO2005089788A1 (ja) | 2004-03-19 | 2005-09-29 | Morinaga Milk Industry Co., Ltd. | 癌治療のための薬剤 |
| US7419667B2 (en) | 2004-03-19 | 2008-09-02 | Morinaga Milk Industry Co. Ltd. | Drug for cancer therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0586932B2 (de) | 1993-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7994217B2 (en) | Prenatal multivitamin/multimineral supplement | |
| US12016906B2 (en) | Pharmaceutical composition for anaemia | |
| Ashmead | The absorption and metabolism of iron amino acid chelate | |
| TW200306845A (en) | Novel chromium (III) alpha amino acid complexes | |
| CN101102762A (zh) | 含铁组合物 | |
| US4493829A (en) | Bio-available succinylated protein-iron derivatives which do not cause gastric lesions, method of preparation and related pharmaceutical compounds | |
| Nagpal et al. | Iron formulations in pediatric practice | |
| US20150246018A1 (en) | N-acetyl l-cysteine chelates and methods for making and using the same | |
| JPS6351337A (ja) | 抗腫瘍剤 | |
| JPS6322525A (ja) | 造血剤 | |
| JPH0648955A (ja) | 消化管細胞賦活化剤 | |
| Christensen et al. | Effects of divalent amino acids on iron absorption | |
| US5284832A (en) | Iron complexes containing conalbumin and its derivatives | |
| WO2018154530A1 (en) | Composition or medical food to extract the dietary iron and boost its bioavailability for iron deficiency (id) and id-anemia | |
| Castle | The Gordon Wilson Lecture. A century of curiosity about pernicious anemia | |
| JPH11292788A (ja) | ピロリ菌感染防御剤 | |
| RU2274003C2 (ru) | Способ комплексной переработки крови сельскохозяйственных животных для получения биологически активного вещества с противоанемическими свойствами на основе гемоглобина, биологически активное вещество с противоанемическими свойствами (варианты) и продукт, его содержащий (варианты). | |
| US4939092A (en) | Proteinaceous derivatives containing iron in highly bioavailable form, preparation thereof and pharmaceutical compositions containing them | |
| JPH04141067A (ja) | 鉄剤、その製造法及び鉄強化食品の製造法 | |
| Gerber | A review of mineral absorption with special consideration of chelation as a method to improve bioavailability of mineral supplements | |
| WO2018189649A1 (en) | Oral compositions for the treatment of iron deficiency disorders | |
| JP3024896B2 (ja) | 貧血改善材 | |
| JPH06199693A (ja) | 虚血性疾患改善治療剤 | |
| KR100768674B1 (ko) | 킬레이트화된 철분 펩타이드의 제조방법 | |
| JPH08283162A (ja) | ミネラル吸収促進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |